Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionGlenmede Trust Co Na
Latest Disclosed Ownership5,339 shares
Latest Disclosed Value $ 2,420,488
Glenmede Trust Co Na reports 12.76% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On February 17, 2026 - Glenmede Trust Co Na filed a 13F-HR form disclosing ownership of 5,339 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $2,420,489 USD as of December 31, 2025. The entity filed a previous 13F-HR on May 15, 2025 disclosing 4,735 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 12.76% during the quarter. The current value of the position is $2,385,625 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,339 604 12.76 2,420 5.45 0.0052
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,735 -90 -1.87 2,296 18.12 0.0123
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,825 732 17.88 1,943 2.10 0.0099
2024-11-13 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,093 -128,725 -96.92 1,904 -96.94 0.0091
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 132,818 -2,263 -1.68 62,254 10.25 0.3156
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 135,081 -39,015 -22.41 56,465 -20.29 0.2831
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 174,096 -20,297 -10.44 70,838 4.79 0.3676
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 194,393 -4,348 -2.19 67,598 7.95 0.3865
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 198,741 -106 -0.05 62,618 -0.05 0.3554
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 198,847 8,144 4.27 62,651 13.76 0.3556
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 190,703 30,980 19.40 55,071 19.09 0.3230
2022-11-16 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 159,723 2,151 1.37 46,245 4.15 0.2915
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 157,572 -3,403 -2.11 44,401 5.70 0.2602
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 160,975 147,028 1,054.19 42,008 1,271.91 0.2062
2022-02-15 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,947 -1,345 -8.80 3,062 10.46 0.0145
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,292 2,493 19.48 2,772 7.48 0.0144
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,799 6,295 96.79 2,579 84.61 0.0133
2021-05-18 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,504 -59,113 -90.09 1,397 -90.99 0.0075
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 65,617 61,958 1,693.30 15,507 1,460.06 0.0853
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,659 550 17.69 994 10.32 0.0060
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,109 594 23.62 901 63.82 0.0055
2020-05-20 2020-03-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 2,515 0 0.00 550 0.00 0.0025
2020-02-12 2019-12-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 2,515 -94 -3.60 550 24.72 0.0025
2019-11-14 2019-09-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 2,609 292 12.60 441 4.01 0.0020
2019-08-13 2019-06-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 2,317 409 21.44 424 21.14 0.0019
2019-05-14 2019-03-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 1,908 -276 -12.64 350 -3.05 0.0016
2019-02-14 2018-12-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 2,184 444 25.52 361 8.08 0.0018
2018-11-15 2018-09-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 1,740 46 2.72 334 15.97 0.0013
2018-11-05 2018-06-30 13F/A-1 VERTEX PHARMACEUTICALS COMMON 92532F100 1,694 -87 -4.88 288 8.27 0.0013
2018-08-15 2018-06-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 1,694 -87 288
2018-05-15 2018-03-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 1,781 0 0.00 266 0.00 0.0011
2018-02-15 2017-12-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 1,781 27 1.54 266 0.38 0.0011
2017-11-14 2017-09-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 1,754 99 5.98 265 47.22 0.0012
2017-08-14 2017-06-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 1,655 0 0.00 180 0.00 0.0009
2017-05-16 2017-03-31 13F/A-1 VERTEX PHARMACEUTICALS COMMON 92532F100 1,655 658 66.00 180 150.00 0.0009
2017-05-15 2017-03-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 997 72
2017-02-14 2016-12-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 997 297 42.43 72 20.00 0.0004
2016-11-14 2016-09-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 700 0 0.00 60 0.00 0.0004
2016-08-05 2016-06-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 700 107 18.04 60 30.43 0.0004
2016-04-28 2016-03-31 13F/A-1 VERTEX PHARMACEUTICALS COMMON 92532F100 593 -158 -21.04 46 -51.06 0.0003
2016-04-26 2016-03-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 593 46
2016-02-11 2015-12-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 751 0 0.00 94 22.08 0.0006
2015-11-12 2015-09-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 751 47 6.68 77 -9.41 0.0006
2015-07-22 2015-06-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 704 -25,470 -97.31 85 -97.25 0.0006
2015-04-29 2015-03-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 26,174 0 0.00 3,087 -0.68 0.0225
2015-02-06 2014-12-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 26,174 72 0.28 3,108 6.04 0.0248
2014-11-14 2014-09-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 26,102 -165 -0.63 2,931 17.90 0.0368
2014-08-13 2014-06-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 26,267 -60 -0.23 2,486 33.58 0.0329
2014-05-07 2014-03-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 26,327 0 0.00 1,861 -4.81 0.0224
2014-01-31 2013-12-31 13F VERTEX PHARMACEUTICALS COMMON 92532F100 26,327 25,423 2,812.28 1,955 2,817.91 0.0251
2013-11-14 2013-09-30 13F VERTEX PHARMACEUTICALS COMMON 92532F100 904 230 34.12 67 26.42 0.0010
2013-08-15 2013-06-30 13F/A-1 VERTEX PHARMACEUTICALS COMMON 92532F100 674 53 0.0008
2013-08-20 2013-06-30 13F/A-2 VERTEX PHARMACEUTICALS COMMON 92532F100 674 674 53 0.0008
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.